Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Forbes Medi-Tech has reported that its cholesterol-lowering drug, FM-VP4 failed to meet its goal in a phase II trial.
Subscribe to our email newsletter
Preliminary data received did confirm that the drug is dose responsive, produces a statistically significant reduction in bad (LDL) cholesterol and has maintained an excellent safety profile. However, FM-VP4 did not achieve the company's established goal of a 15% average reduction in bad cholesterol from baseline.
“While we acknowledge that the results of the trial do not support a blockbuster market potential for FM-VP4, there is a significant market for alternative LDL-lowering products,” said Charles Butt, CEO of Forbes Medi-Tech. “The company will review further data as it becomes available in the next few weeks and will continue to assess out-licensing opportunities in North America and international markets.”
“There is potential for FM-VP4 to provide at least the same incremental benefit but without the safety concerns associated with higher doses of statins,” added Charles Butt.